Parents Are Paying $50,000 to Pick Their Babies’ Eye Color and IQ. Some Experts Say This Is ‘Very Troubling.’

Parents shelling out $50,000 to select embryos for traits like eye color and even IQ marks a bold leap in biotech innovation. This isn't some distant dream—it's happening now through startups like Herasight, Nucleus Genomics, and Orchid Health, which leverage polygenic risk scores to predict outcomes from height to disease risks. Founders frame it as 'genetic optimization,' promising healthier, smarter children, and they've already screened thousands of embryos for hundreds of families.

In my experience coaching entrepreneurs, this rush into embryo selection highlights the double-edged sword of cutting-edge tech. On one hand, it's exciting for investors eyeing biotech's potential to transform lives; on the other, experts like those from the Center for Genetics and Society are sounding alarms about dystopian risks and scientific immaturity. Bioethicists fear a divided society of 'superhumans,' and the American College of Medical Genetics warns the data isn't robust enough yet.

The tension here is palpable: innovation vs. ethics in an era where startups are pushing boundaries faster than regulations can catch up. As someone who's seen entrepreneurs navigate investor scrutiny, I appreciate the drive but urge caution—rushing ahead without ethical guardrails could backfire spectacularly.

Dive into the full article to explore how this tech could reshape our future and what it means for the bold ventures leading the charge.